Name (Synonyms) | Correlation | |
---|---|---|
drug137 | Bromhexine Hydrochloride Tablets Wiki | 0.35 |
drug569 | Nutrition support Wiki | 0.35 |
drug683 | Recombinant Human Interferon α2b Spray Wiki | 0.35 |
drug59 | Arbidol Hydrochloride Granules Wiki | 0.35 |
drug339 | Halo Oral Spray Wiki | 0.35 |
drug376 | Hydroxychloroquine Sulfate (HCQ) Wiki | 0.35 |
drug340 | Halo Placebo Wiki | 0.35 |
drug901 | Vitamin D Wiki | 0.20 |
drug872 | UC-MSCs Wiki | 0.18 |
drug616 | Placebo Wiki | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
D008107 | Liver Diseases NIH | 0.35 |
D016638 | Critical Illness NIH | 0.18 |
D018352 | Coronavirus Infections NIH | 0.14 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.12 |
D011014 | Pneumonia NIH | 0.09 |
D003141 | Communicable Diseases NIH | 0.08 |
D014777 | Virus Diseases NIH | 0.08 |
D011024 | Pneumonia, Viral NIH | 0.06 |
D007239 | Infection NIH | 0.06 |
There are 8 clinical trials
COVID-19 may cause another world-wide epidemic. This study is divided into 2 arms: (1) Prospective longitudinal observational study involving patients with laboratory-confirmed COVID-19 and (2) Retrospective study on patients with laboratory-confirmed COVID-19. Arm 1: We will collect EDTA blood, stool samples, rectal swab, urine, saliva, and specimens from upper respiratory tract (nasopharyngeal aspirate or flocked swab), and lower respiratory tract (sputum or tracheal aspirate) on daily, alternate day, or weekly basis as appropriate. Arm 2: The remainder of specimens that were submitted for laboratory investigation as part of clinical management will be retrieved. Those specimens will only be used after all clinically indicated testing and confirmation procedures have been completed. Assistance from the Public Health Laboratory Service, Department of Health, will be invited to retrieve samples as well as participate in this study. Patients hospitalized for pneumonia in medical wards and ICU at the Prince of Wales Hospital tested negative for COVID-19 will be recruited as controls. Understanding the clinical, virological, microbiological and immunological profiles of this infection is urgently needed to facilitate its management and control.
Description: Patients' treatment and management during hospitalization.
Measure: Clinical Time: 6 monthsDescription: Serial viral load changes during hospitalization.
Measure: Virological Time: 6 monthsDescription: Alterations in fecal microbiota composition (including virome, bacteria and fungi) in COVID-19 patients compared with healthy controls.
Measure: Microbiological Time: 6 monthsCurrently, limited data is available about patients with HIV in the context of the COVID-19 pandemic. People with HIV who have not achieved viral suppression through antiretroviral treatment may have a compromised immune system that leaves them vulnerable to infections and disease progression. However, little is known about the presentation and clinical outcomes of patients with HIV and SARS-CoV-2. Our aim is to characterize the clinical presentation and disease course of COVID-19 in patients with HIV.
Description: COVID-19 related death among patients with HIV and COVID-19
Measure: Mortality Time: 30 daysDescription: Percentage of patients who required hospitalization
Measure: Frequency of patients requiring hospital admissions Time: 30 daysDescription: Percentage of patients who required ICU admission
Measure: Frequency of patients requiring ICU admissions Time: 30 daysDescription: Percentage of patients who required respiratory support (new oxygen use, non-invasive ventilation,or invasive ventilation)
Measure: Frequency of respiratory support use Time: 30 daysDescription: Percentage of patients who developed acute kidney injury defined as increase in baseline creatinine, or use of renal replacement therapy
Measure: Frequency of kidney injury Time: 30 daysDescription: Percentage of patients who developed liver injury defined as increase in baseline ALT
Measure: Frequency of liver injury Time: 30 daysSince December 2019, a new agent, the SARS-Cov-2 coronavirus has been rapidly spreading from China to other countries causing an international outbreak of respiratory illnesses named COVID-19. In France, the first cases have been reported at the end of January with more than 60000 cases reported since then. A significant proportion (20-30%) of hospitalized COVID-19 patients will be admitted to intensive care unit. However, few data are available for this special population in France. We conduct a large observational cohort of ICU suspected or proven COVID-19 patients that will enable to describe the initial management of COVID 19 patients admitted to ICU and to identify factors correlated to clinical outcome.
Description: Mortality at day 28
Measure: Mortality at day 28 Time: day 28Description: severe complications (pulmonary embolism, acute kidney injury, myocarditis, cardiac arrest, liver failure, ventilator associated pneumonia) Yes / No
Measure: severe complications Time: up to day 28Description: Delay in imaging in hours
Measure: Imaging Time: day 1Description: delay in microbiological diagnosis in hours
Measure: Delay in Microbiological diagnosis Time: day 1Description: Antiviral therapy Yes / no
Measure: Antiviral therapy Time: up to day 28Description: Antibiotic therapy Yes / No
Measure: Antibiotic therapy Time: day 28Description: Covid-19 treatments Yes / No
Measure: Covid-19 treatments Time: up to day 28Description: number
Measure: Patients receiving renal replacement therapy Time: up to day 28Description: number
Measure: Patients receiving mechanical ventilation Time: up to day 28Description: Patient alive at day 28 : yes / No
Measure: Vital status Time: day 28Multicenter observational/registry study of the clinical features and outcomes of critically ill patients with COVID-19.
The current outbreak of COVID-19 pandemic has been marked by severe psychological problems. People around the world experienced a similarly frightening public health emergency, on a global scale, with the spread of this corona infection. (1) Studies of the Severe Acute Respiratory Syndrome (SARS) outbreaks that occurred in Canada, Taiwan, and Hong Kong found that the enormous emotional burden carried by those health care workers who were on the front lines of the battle against the disease led to psychological morbidity like anxiety, stress and even further leads to Post traumatic stress disorder. The initial phase of the COVID-19 outbreak in China in 2020 also reported more than half of the respondents rated the psychological impact as moderate-to-severe, and about one-third reported moderate-to-severe anxiety in general population.(2) - The chances of Fear, anxiety and stress are even higher in Individuals with preexisting liver disease as they have restriction of services for getting treatment. Moreover, they can have the following additional issues: - Fear of severe form of Corona present (as presented in most of the media and research) - Fear of dying - Added uncertainty - Family members also worried
Description: Following questionnaire will be used For Fear of COVID-19: FEAR OF COVID-19 Scale Fear of Coronavirus-19 Scale: The participants indicate their level of agreement with the statements using a five-item Likert-type scale. Answers included "strongly disagree," "disagree," "neither agree nor disagree," "agree," and "strongly agree". The minimum score possible for each question is 1, and the maximum is 5. A total score is calculated by adding up each item score (ranging from 7 to 35). The higher the score, the greater the fear of cororonavirus-19.
Measure: Assessment of the fear levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS) Time: Day 0Description: Following questionnaire will be used o For, anxiety: DASS - 21 Scale Depression, Anxiety and Stress Scale - 21 Items (DASS-21) Depression Anxiety Stress Scale (DASS)-21: The DASS-21 is based on three subscales of depression, stress, and anxiety and each subscale consists of seven questions each. Each subscale comprises of seven statements regarding how the test subject was feeling over the last week and four responses ranging from 0- did not apply to me at all, 1- applied to me some of the time, 2- applied to me for a considerable amount of time to 3- applied to me very much/most of the time. The scoring system is of the Likert type and the total score for each subscale gives the severity of that very symptom which has a range from 0 to 21 for each subscale.
Measure: Assessment of the anxiety levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS) Time: Day 0Description: Following questionnaire will be used o Stress levels: DASS - 21 Scale Depression Anxiety Stress Asymptomatic ≤4 ≤3 ≤7 Symptomatic >4 >3 >7
Measure: Assessment of the stress levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS) Time: Day 0Description: Following questionnaire will be used o For Fear of COVID-19: FEAR OF COVID-19 Scale
Measure: Association between presence of Liver disease and fear levels Time: Day 0Description: Following questionnaire will be used o For, anxiety levels: DASS - 21 Scale Depression, Anxiety and Stress Scale - 21 Items (DASS-21) Higher Scores mean worse condition
Measure: Association between presence of Liver disease and anxiety levels Time: Day 0Description: Following questionnaire will be used o For stress levels: DASS - 21 Scale Depression, Anxiety and Stress Scale - 21 Items (DASS-21) Higher Scores mean worse condition.
Measure: Association between presence of Liver disease and stress levels Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between Fear and Child-Turcotte-Pugh Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between anxiety and Child-Turcotte-Pugh Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between stress and Child-Turcotte-Pugh Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between fear and Model for End Stage Liver Disease Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between anxiety and Model for End Stage Liver Disease Score Time: Day 0Description: Higher Scores mean worse condition
Measure: Correlation between stress and Model for End Stage Liver Disease Score Time: Day 0This is a prospective multicenter cohort study. The question arises as to whether treatment with protease inhibitors (PIs) could have a preventive role for COVID-19 infection, especially since patients living with HIV (PLWHIV) have not been described as more at risk of developing COVID-19 infection. The aim of our study will therefore be to assess the impact of long-term protease inhibitors in PLWHIV on the incidence of COVID-19.
Description: Occurrence of COVID-19 infection during the epidemics (M0, M1) in both study groups
Measure: Comparison of the incidence of COVID-19 infection in PLWHIV treated with long-term antiretroviral drugs including a protease inhibitor and those without a protease inhibitor Time: 1 monthDescription: Percentage of positive serological tests at the end of the epidemics in both study groups
Measure: Determination of the seroprevalence of COVID-19 infection in both groups of the study Time: 6 monthsDescription: Proportion of severe forms in both study groups
Measure: Comparison of the severity of COVID-19 infection symptoms in both groups of the study. Time: 6 monthsDescription: Statistical association between a risk factor and the occurrence of COVID-19 infection in both study groups
Measure: Identification of potential risk factors for COVID-19 infection in HIV patients treated with protease inhibitor or without protease inhibitor Time: 6 monthsThis study aims at investigating handwashing behavior during COVID-19 pandemic. It was hypothesized that social-cognitive and emotional predictors as well as COVID-19 morbidity and mortality rates within the country would be associated with handwashing behavior in the general population of adults in 14 countries.
Description: The 12-item self-report measure of adherence to handwashing guidelines across situations (e.g., after visiting public spaces, after touching garbage, etc.) based on the guidelines issued by the World Health Organization and the Centers for Disease Control and Prevention. The responses are provided on a 4-point scale, ranging from 1 (strongly disagree) to 4 (strongly agree). Higher scores indicate better outcomes (the higher level of adherence to handwashing guidelines).
Measure: Handwashing adherence Time: 1 monthDescription: The 1-item self-report measure of the frequency of handwashing (for at least 20 seconds, all surfaces of the hands) daily. The responses are provided on a 4-point scale, ranging from 1 (less than once) to 5 (more than 10 times). Higher scores indicate better outcomes (the higher frequency of handwashing).
Measure: Frequency of handwashing Time: 1 monthDescription: 4 self-efficacy questionnaire items; mean item score ranging from 1 to 4, higher scores indicate stronger self-efficacy
Measure: Self-efficacy Time: 1 monthDescription: 3 questionnaire items to assess risk perception; mean item score ranging from 1 to 5, higher scores indicate higher risk perception
Measure: Risk perception Time: 1 monthDescription: 4 items assessing positive (1 item) and negative (1 items) outcome expectancies; mean item scores ranging from 1 to 4, higher scores indicate more positive outcome expectancies
Measure: Outcome expectancy Time: 1 monthDescription: 2 questionnaire items assessing intention to adhere to handwashing recommendations; mean item scores ranging from 1 to 4, higher scores indicate stronger intention to wash hands (for at least 20 seconds, all surfaces of the hands)
Measure: Intention Time: 1 monthDescription: 2 questionnaire items assessing action planning (1 item) and coping planning (1 item); mean item scores ranging from 1 to 4, higher scores indicate a higher level of self-reported planning
Measure: Planning Time: 1 monthDescription: 3 questionnaire items assessing a facet of action control, namely self-monitoring; mean item scores ranging from 1 to 4, higher scores indicate a higher level of self-reported monitoring of handwashing behavior
Measure: Action control Time: 1 monthDescription: 1 questionnaire item assessing perceptions of handwashing as an effective means of preventing coronavirus SARS-CoV-2 infection; item scores ranging from 1 to 4, higher scores indicate a higher level of perceived effectiveness of hand hygiene
Measure: Perceived effectiveness of hand hygiene Time: 1 monthDescription: 7-item self-report scale (Generalized Anxiety Disorder, GAD-7) scale to assess anxiety symptoms; mean item scores ranging from 1 to 4, higher scores indicate a higher level of generalized anxiety
Measure: Anxiety Time: 1 monthDescription: The daily cumulative numbers for COVID-19 morbidity and mortality in the study countries. Published daily as the Situation Report by World Health Organization, starting on 21 January 2020. Higher numbers indicate the higher cumulative COVID-19 morbidity and mortality rates in the country.
Measure: Country-level COVID-19 morbidity and mortality rates Time: 60 daysTo compare various treatments provided to positive COVID-19 patients at locations across the OSF Ministry. Provide the opportunity to compare the effectiveness of various treatments and treatment timelines provided to specific cohorts of patients that have the potential to impact future treatment plans for COVID-19 patients and/or future research hypotheses.